MetaVia Inc. (MTVA)vsBeiGene, Ltd. (ONC)
MTVA
MetaVia Inc.
$1.66
-1.19%
HEALTHCARE · Cap: $7.38M
ONC
BeiGene, Ltd.
$372.49
-0.88%
HEALTHCARE · Cap: $42.08B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 10.7% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 62/100 (C+).
MTVA
Avoid23
out of 100
Grade: F
ONC
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MTVA.
Margin of Safety
+80.2%
Fair Value
$1776.44
Current Price
$372.49
$1403.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Revenue surging 29.6% year-over-year
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 8.1x book value
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MTVA
The strongest argument for MTVA centers on Price/Book, Debt/Equity.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, Revenue Growth. Revenue growth of 29.6% demonstrates continued momentum. PEG of 1.07 suggests the stock is reasonably priced for its growth.
Bear Case : MTVA
The primary concerns for MTVA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are Price/Book, P/E Ratio, Altman Z-Score. A P/E of 66.7x leaves little room for execution misses.
Key Dynamics to Monitor
MTVA profiles as a value stock while ONC is a growth play — different risk/reward profiles.
MTVA carries more volatility with a beta of 0.90 — expect wider price swings.
ONC is growing revenue faster at 29.6% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (62/100 vs 23/100) and 29.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MetaVia Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
MetaVia Inc. is an innovative technology company dedicated to delivering advanced digital solutions that enhance connectivity and productivity across multiple sectors. Leveraging cutting-edge artificial intelligence and cloud computing technologies, MetaVia crafts tailored platforms that address complex client challenges, positioning itself as a leader in the industry. The firm's commitment to sustainability and social responsibility not only aligns with current market needs but also underscores its long-term growth strategy. As MetaVia navigates the dynamic tech landscape, it is well-placed to generate significant value for shareholders.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?